Neurotrophins have profound effects on synaptic function and structure. They can be derived from presynaptic, as well as postsynaptic, sites. To date, it has not been possible to measure the release of neurotrophins from axon terminals in intact tissue. We implemented a novel, extremely sensitive assay for the release and transfer of anterogradely transported neurotrophin-3 (NT-3) from a presynaptic to a postsynaptic location that uses synaptosomal fractionation after introduction of radiolabeled NT-3 into the retinotectal projection of chick embryos. Release of the anterogradely transported NT-3 in intact tissue was assessed by measuring the amount remaining in synaptosomal preparations after treatment of whole tecta with pharmacological agents. Use of this assay reveals that release of NT-3 from axon terminals is increased by depolarization, calcium influx via N-type calcium channels, and cAMP analogs, and release is most profoundly increased by excitation with kainic acid or mobilization of calcium from intracellular stores. NT-3 release depends on extracellular sodium, CaM kinase II activity, and requires intact microtubules and microfilaments. Dantrolene inhibits the high potassium-induced release of NT-3, indicating that release of calcium from intracellular stores is required. Tetanus toxin also inhibits NT-3 release, suggesting that intact synaptobrevin or synaptobrevin-like molecules are required for exocytosis. Ultrastructural autoradiography and immunolabel indicate that NT-3 is packaged in presumptive large dense-core vesicles. These data show that release of NT-3 from axon terminals depends on multiple regulatory proteins and ions, including the mobilization of local calcium. The data provide insight in the mechanisms of anterograde neurotrophins as synaptic modulators. ; presynaptic terminals; calcium; axonal transport; neurotrophin; synapse; synaptic transmission Neurotrophins are important regulators of neuronal differentiation and synaptic plasticity (Lohof et al., 1993; Snider, 1994; Kang and Schuman, 1995; Thoenen, 1995; McAllister et al., 1999; Poo, 2001) . Traditionally, neurotrophins were believed to be derived by retrograde axonal transport from target cells, but recent studies revealed that neurotrophins are also transported anterogradely along axons (von Bartheld et al
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Neurotrophins are important regulators of neuronal differentiation and synaptic plasticity (Lohof et al., 1993; Snider, 1994; Kang and Schuman, 1995; Thoenen, 1995; McAllister et al., 1999; Poo, 2001) . Traditionally, neurotrophins were believed to be derived by retrograde axonal transport from target cells, but recent studies revealed that neurotrophins are also transported anterogradely along axons (von Bartheld et al., 1996; Zhou and Rush, 1996; Altar et al., 1997; Conner et al., 1997; Heymach and Barres, 1997; Smith et al., 1997; Yan et al., 1997; Fawcett et al., 2000; von Bartheld and Butowt, 2000) and may act as extremely potent excitatory neurotransmitters (Kafitz et al., 1999) . Anterograde signals provide trophic support from afferents (Linden, 1994; von Bartheld et al., 1996; Altar et al., 1997) , may mediate fast, local effects at synaptic sites (Lohof et al., 1993; Kang and Schuman, 1995; Thoenen, 1995; Kafitz et al., 1999; Poo, 2001) , and regulate dendritic growth, neuronal cytoarchitecture, and phenotypes (Altar et al., 1997; McAllister et al., 1999; Fawcett et al., 2000) .
Neurotrophin 3 (NT-3) enhances synaptic transmission in neuromuscular junctions (Lohof et al., 1993) and the brain (Kim et al., 1994) , alters short-term and long-term plasticity (Kang and Schuman, 1995; Kokaia et al., 1998) , and modifies the morphology of cerebellar and cortical neurons (Lindholm et al., 1993; McAllister et al., 1999) . In the retinotectal system, endogenous and exogenous NT-3 are moved by anterograde axonal transport , and exogenous NT-3 is released from retinotectal terminals and taken up by tectal dendrites, promoting the survival of postsynaptic neurons (von Bartheld et al., 1996) . Release mechanisms are crucial for an understanding of the action of neurotrophins (Lo, 1995; Thoenen, 1995; Fawcett et al., 1997; Aloyz et al., 1999; Berninger and Poo, 1999; Schinder and Poo, 2000) , but mechanisms of the release of anterogradely transported neurotrophins are completely unknown. Neuropeptides are released by a variety of mechanisms, presumably by packaging into different types of vesicles that are released by different mechanisms (Bartfai et al., 1988; Hille et al., 1999; Kasai, 1999) . Therefore, release mechanisms of neurotrophins cannot be predicted on the basis of what is known for other neuropeptides. The role of anterogradely transported neurotrophins has been particularly difficult to assess because of the absence of an assay that localizes the trophic factors within synapses and is sufficiently sensitive to measure the excessively small amounts released from axon terminals.
We developed a technique that allows us to measure the release and transynaptic transfer of picomolar amounts of anterogradely transported NT-3. A novel combination of autoradiographic, biochemical, and experimental pharmacological techniques in an in ϩ Krebs' buffer (in mM): 134 NaC l, 5 KC l, 1 MgSO 4 ⅐ 7 H 2 O, 1.25 K H 2 PO 4 , 2.0 CaCl 2 ⅐ 2 H 2 O, 16 NaHC O 3 , and 10 glucose, pH 7.5 (after gassing with 95% O 2 , 5%C O 2 )] to remove radioactivity that had leaked into systemic circulation. The perf usion was also used to deliver pharmacological agents directly to the brain and to improve penetration. The tectum was removed and placed in cold low K ϩ buffer, and its radioactivity was counted in a gamma counter. Only tecta containing Ͼ6000 cpm (n ϭ 694) were used for subsequent release experiments, because such tecta typically generated Ͼ200 cpm in synaptosomes and we found that ϳ200 cpm were necessary to reliably quantif y synaptosomal peaks. Each dissected tectum was incubated in 3 ml of oxygenated low K ϩ buffer (6 mM K ϩ ) or oxygenated high K ϩ buffer (56 mM K ϩ ) (in mM: 84 NaC l, 55 KC l, 1 MgSO 4 ⅐ 7 H 2 O, 1.25 K H 2 PO 4 , 2 CaCl 2 ⅐ 2 H 2 O, 16 NaHC O 3 , and 10 glucose) at room temperature with or without experimental drugs for 60 min, unless indicated otherwise. Maximal transport capacity in the retinotectal projection was tested by injection of 2-400 ng (ϳ0.5-30 ϫ 10 6 cpm in the eye at the time the animal was killed) and gammacounting of tecta after 20 hr. The amount of injected 125 I-labeled N T-3 in the eye and the amount of anterogradely transported N T-3 in the tectum was quantified; in addition, the amount of the radioactivity in the synaptosomal peaks was taken as a measure for the amount and percentage of 125 I-labeled N T-3 within the presynaptic terminals [excluding the amount in the general membrane fraction containing the bulk of tectal radioactivity: axons and dendrites (von Bartheld et al., 1996) ].
Synaptosome preparation, data collection, and analysis
Synaptosomes were prepared to measure how much 125 I-labeled N T-3 remained in presynaptic terminals. The protocol of Viglietti et al. (1977) was used with slight modifications. The incubation buffer was replaced with 5 ml of 0.32 M sucrose and 5 mM Tris, pH 7.4 (buffer B); tecta were homogenized by trituration using a 1 ml syringe with a 20 G 1 1/2 gauge needle. The suspension was centrif uged at 4°C for 10 min at 1500 ϫ g to remove the crude nuclear fraction (P1). The pellet was washed two times with 1 ml buffer B, and supernatants were removed and centrif uged at 17,000 ϫ g for 20 min to pellet the membrane fraction (P2). Pellet 1 and supernatant (S2) were counted in a gamma counter. P2 was resuspended in 10 ml of 0.32 M sucrose and loaded on a two-step discontinuous ficoll -sucrose gradient in Quick-Seal tubes containing 15 ml of 13% (w/ v) ficoll in 0.32 M sucrose and overlaid with 15 ml of 7.5% (w/ v) ficoll in 0.32 M sucrose. The samples were centrif uged at 53,000 ϫ g for 90 min at 4°C. The ultracentrif uge tubes were fractionated (50 ϫ 0.8 ml fractions), and each fraction was counted for 10 min in a gamma counter. The radioactivity within the synaptosomal peak (defined by visual inspection of the printed plots) was calculated as the ratio (divided by the total radioactivity in the ultracentrif uge tube). The average ratio of the synaptosomal peak in low K ϩ buffer was defined as 100% unless indicated otherwise. The ratio of the synaptosomal peak /tube in the experimental condition was divided by the average ratio of the synaptosomal peak /tube in the low K ϩ buffer to calculate the percentage of N T-3 released from retinotectal terminals. Statistical significance was determined by unpaired Student's t test or, for multiple comparisons, by one-way ANOVA with Prism 2.01 software.
Proteins extracted from synaptosomal fractions derived from 125 I-N T-3-loaded tecta were examined by SDS-PAGE (15% gels). To examine whether release of N T-3 from synaptosomal fractions (obtained from 125 I-N T-3-loaded tecta) can be measured, synaptosomes were centrif uged and resuspended in either high or low K ϩ buffer, warmed to 37°C, gassed for 60 min, and centrif uged again in either a microcentrif uge or the ultracentrif uge. The pellets and supernatants were gamma counted to determine release of 125 I-N T-3 into the buffer.
Pharmacological manipulations of release
A total of 694 successf ul release experiments were performed to test molecules potentially involved in release of N T-3. Control experiments (low K ϩ or high K ϩ ) were included in each experimental series of up to eight centrif ugation tubes for calibration of N T-3 release ("quality control"). For manipulation of release in vitro, the dissected tecta were incubated with 3 ml of high K ϩ buffer containing one of the following agents: 4-aminopyridine (1 mM), 8-Br-cAM P (50 M), cadmium chloride (100 M), colchicine (175 M), cytochalasin D (0.2 M), dantrolene (50 M), forskolin (10 M), K N-93 (10 M), K N-92 (10 M), nifedipine (10 M), -conotoxin-GV IA (0.1 M), strophanthidin (500 M), tetrodotoxin (3 M), or thapsigargin (5 M). When drugs required dissolving in DMSO or ethanol, control tecta were tested with identical vehicle solution.
BA PTA. Buffers were prepared as described, except that C aC l 2 was replaced with MgC l 2 at the same concentration. BAP TA AM (10 M) or BAP TA (20 or 200 M) was added to the calcium-free buffers overnight before use. Higher BAP TA concentrations were necessary because tecta were a source of calcium that leaked into the incubation solution. C alcium concentrations in the incubation buffer were measured with and without tecta, and with normal calcium, or calcium-free buffers containing 20 M BAP TA, 200 M BAP TA, or 10 M BAP TA AM. C alcium electrodes and calibration buffers were used as described previously (Baudet et al., 1994) .
N-Methyl-D-glucamine. N-Methyl-D-glucamine (NMG) was used to replace extracellular sodium in high K ϩ buffer (in mM: 100 NMG-HC l, 39 KC l, 1 MgSO 4 , 1.25 K H 2 PO 4 , 2 CaCl 2 , 16 KHCO 3 , and 10 glucose). Chick embryos were perf used with high K ϩ buffer containing NMG, dissected optic tecta were incubated in NMG buffer for 60 min, and the tissue was f urther processed as described. Some NMG-treated tecta were incubated in normal (Na-containing) high K ϩ buffer to determine whether the NMG effect was reversible.
Tetanus toxin. Tetanus toxin (1-4 g) was injected into the eyes 1 d before N T-3 injection to target the toxin by anterograde axonal transport to the retinotectal nerve terminals. Whereas 4 g was lethal, 1-2 g was tolerated. The tetanus toxin C fragment (responsible for trafficking of the molecule) was radio-iodinated with lactoperoxidase to a specific activity of 40 -61 cpm /pg. Free iodide was removed by membrane centrif ugation (von Bartheld, 2001) . Radiolabeled toxin C fragment (300 ng) was injected into the eye of chick embryos, and the tecta were processed for autoradiography to confirm that the toxin was transported anterogradely by retinal ganglion cell (RGC) axons to the optic tectum.
125 I-N T-3 was coinjected with (cold) tetanus toxin to test whether the toxin interfered with the normal anterograde transport of N T-3. The tecta, loaded with tetanus toxin and 125 I-N T-3, were treated with high K ϩ buffer and processed as described.
Control experiments
To determine whether N T-3 was released constitutively during the incubation in low K ϩ buffer, the amount of N T-3 in retinotectal terminals was compared between tecta processed immediately after killing, and tecta were incubated for 60 min in oxygenated low K ϩ buffer. To determine whether N T-3 or other neurotrophins or peptides bound to terminals during the preparation of synaptosomes, the tectal homogenates of normal (not injected) chick embryos were incubated with 0.1-0.3 ng /ml radio-iodinated N T-3, BDN F, NGF, SP, or cytochrome c and subjected to ficoll -sucrose gradient centrif ugation, and gamma counts were plotted after fractionation. Some N T-3 preparations were incubated with 500-fold excess cold N T-3 to determine specific, receptor-mediated binding. Total protein content of synaptosomal peaks was measured by UV absorption [Bio-Rad (Hercules, CA) standard protein assay].
Anterograde transport and release of other proteins
To compare the transport and release of N T-3 with that of other proteins, we measured NGF, tetanus toxin C fragment, and cytochrome c. These proteins were chosen because, unlike substance P, they can be transported in the retinotectal system after intraocular injection. The amount of radiolabeled protein injected in the eye was measured 20 hr later to assess retention in the eye. The transport efficiency was measured by comparing the amount in the eye at the time the animal was killed with the amount contained in the contralateral tectum. By competing with excess cold protein (20-to 50-fold), it was examined whether anterograde transport was receptor mediated. Accumulation of the transported protein in retinotectal terminals was assessed by measuring the radioactivity in the synaptosomal peak and comparing it with the total radioactivity in the contralateral tectum.
In vivo release of NT-3
Kainic acid (8 l, 5 mM) was injected into the eye (estimated concentration in the eye, 0.625 mM) of 125 I-N T-3 treated chick embryos 45 min before dissection of the tecta. To determine whether the effect of the kainic acid could be blocked by TTX, 5 l of TTX (100 M) or PBS (as a control for the TTX application) was injected into the eyes, followed by 8 l of kainic acid (5 mM) 15 min later. The embryos were anesthetized 45 min later and perf used intracardially, and the tecta were processed as described.
Release of substance P from tectal terminals
Radio-iodinated N T-3 was injected in the eye 20 hr before homogenization of the tecta to identif y the fractions containing the synaptosomal peak. Tecta were treated with either low or high K ϩ buffer as described. Fractions were counted in the gamma counter for 1 min. HC l was added to 3 ml fractions containing synaptosomes, and samples were stored immediately at Ϫ80°C. Samples of 500 l were analyzed by radioimmunoassay for the content of SP (Chen et al., 1996) .
Vesicle purification
Tecta from E17 chick embryos loaded with 125 I-labeled N T-3 were dissected and homogenized at 4°C in 15 ml of buffered sucrose (4 mM H EPES and 320 mM sucrose, adjusted to pH 7.3 with NaOH). Vesicles were purified according to Huttner et al. (1983) and Han and Fischbach (1999) . After centrif ugations, resuspended vesicles (6.7 ml) were loaded on sucrose step gradients in 40 ml Quick-Seal centrif uge tubes, loaded with 6.75 ml each of 50, 200, 400, 550, and 800 mM sucrose (from bottom to top), and centrif uged at 24,500 rpm (42.1 rotor; 65,000 ϫ g) for 5 hr. Fractions were collected, counted, and plotted as described for synaptosome fractionations.
Electron microscopic autoradiography and immunocytochemistry
L ocalization and quantification of anterogradely transported 125 I-N T-3 in tectal tissue was performed by autoradiography as described previously (von Bartheld et al., 1996; von Bartheld, 2001) . Five hundred thirty silver grains from two E17 tecta with 125 I-N T-3-loaded retinotectal terminals were analyzed. Silver grains overlying presynaptic or postsynaptic compartments were quantified, and the percentages of silver grains were calculated. In addition, 87 silver grains within the stratum opticum were analyzed for association with either endosomes or large densecored vesicles (LDC Vs) within axons. Synaptosomes from 125 I-N T-3-loaded tecta were fixed in 2.5% glutaraldehyde and centrif uged at 10,000 ϫ g at 4°C, embedded in Spurr, and sectioned at 80 -90 nm.
Sections were coated with a monolayer of I lford L4 emulsion and exposed for 8 -10 weeks at 4°C. Developed sections were examined on a Philips C M10 transmission electron microscope. The distribution of silver grains was photographed, and 94 random silver grains were quantified at a magnification of 15,000 -20,000ϫ. For immunolabeling, tectal tissue from E19 -E20 embryos was fixed in 4% paraformaldehyde and 0.1% glutaraldehyde by intracardial perf usion. Standard pre-embedding immunolabeling techniques were used. Tecta were sectioned with a vibratome at 100 -150 m. Endogenous peroxidase activity was quenched by pretreatment with 3% H 2 O 2 . The sections were incubated for 24 hr at 4°C with 20 g /ml purified polyclonal antibodies to N T-3 (Z hou and Rush, 1993) (courtesy of R. Rush, Flinders University, Adelaide, Australia) and processed with the ABC kit (Vector Laboratories, Burlingame, CA). Sections were embedded in Spurr and thin sectioned at 80 -90 nm. In control sections, the primary antibody was omitted.
RESULTS

Anterogradely transported 125 I-NT-3 in tectal terminals can be quantified
Injections of 40 -80 ng of 125 I-NT-3 in the eye resulted in a total of ϳ100 pg of 125 I-NT-3 in the contralateral tectum. The synaptosomal peaks contained 5.94 Ϯ 0.36% (SEM; n ϭ 19) of the total radioactivity measured in the contralateral tectum, equivalent to 15-20% of the radioactivity in the ultracentrifugation tube ( Fig.  1 A) . Much of the radioactivity was found in the general membrane fraction, containing 125 I-NT-3 in retinal axons en route to their terminals in the tectum (von Bartheld et al., 1996) . There was no radioactive peak in the synaptosomes from the ipsilateral (control) tecta, indicating that accumulation of 125 I-NT-3 in tectal synaptosomes was not attributable to diffusion or uptake after leakage into systemic circulation, and 125 I-NT-3 arrived in the tectum intact. The localization of anterogradely transported 125 I-NT-3 in synaptosomes (after fractionation) was confirmed by quantitative autoradiography at the ultrastructural level. Synaptosomes were identified in expected quality and quantity (Ϸ60 -70% purity) (Viglietti et al., 1977) , and Ͼ60% of silver grains were located over clearly identified synaptosomes ( Fig. 1 B, C) . The identity of synaptosomal fractions was verified by increased levels of synaptic vesicle protein (SV2) in Western blots (data not shown). The association of radiolabeled NT-3 in synaptosomal peaks with retinotectal terminals (rather than other tectal terminals) can be concluded because of the fact that the highest level of autoradiographic labeling in the tectum in situ occurs in the layer known to contain the retinotectal terminals (von Bartheld et al., 1996) . To determine whether 125 I-NT-3 in multivesicular bodies (MVBs) of postsynaptic dendrites may contribute to the radioactivity in the synaptosomal peak, silver grains over MVBs were quantified. Only ϳ2% of silver grains labeled MVBs (Fig. 1C) , ruling out significant contamination by these and other postsynaptic elements. These data confirm that synaptosomal fractionation measures the content of anterogradely transported 125 I-NT-3 in retinotectal terminals.
I-NT-3 in presynaptic terminals in situ: quantitative electron microscopy
To verify the amount of 125 I-NT-3 in the presynaptic retinotectal terminals in situ, quantitative autoradiography was performed at the ultrastructural level. Typical examples of silver grains over presynaptic and postsynaptic profiles are shown in Figure 1 
D-F.
A total of 530 silver grains from two chick tecta were sampled randomly, and their location was analyzed at a magnification of 24,400ϫ. In many (42.5%) but not all of the labeled terminals, LDCVs were visible in close vicinity (within Ϸ100 nm) of the silver grains ( Fig. 1 E) , consistent with the notion that anterograde neurotrophins localize in LDCVs (Fawcett et al., 1997; Michael et al., 1997; Holstege et al., 1999) . The percentage of silver grains over presynaptic terminals was 5.48% (range, 4.72-6.17%) of the total 530 grains, and 3.15% were over postsynaptic terminals ( Fig. 1 E, F ) . The percentage for presynaptic localization of 125 I-NT-3 (5.48%) is remarkably similar to that obtained by synaptosomal fractionation (5.94%). Although we cannot rule out coincidence, this similarity supports the validity of our assay for the measurement of exogenous NT-3 in presynaptic axon terminals.
I-NT-3 in synaptosomes is intact by SDS-PAGE
At least some of the NT-3 that arrives in the tectum after anterograde axonal transport from the eye is intact (von Bartheld et al., 1996) , but it was not known whether this included the 125 I-NT-3 within synaptosomes. Protein extracted from synaptosomal fractions was examined by SDS-PAGE. The large majority of 125 I-NT-3 recovered from synaptosomes was intact compared with native 125 I-NT-3 (Fig. 2 A) . When treated with detergents and trypsin, a major fraction of NT-3 in the synaptosomal fraction was degraded, indicating that NT-3 was located within a membrane-confined compartment (data not shown). These results indicate that anterogradely transported NT-3 within synaptosomes remains intact.
Direct release from synaptosomes using the conventional assay
We attempted to measure release of anterogradely transported 125 I-NT-3 directly from synaptosomes by using a conventional static release protocol (Androutsellis-Theotokis et al., 1996) , with the modification that 125 I-NT-3 was loaded into tectal synaptosomes via anterograde transport from the retina in vivo. After injections of 50 -100 ng of 125 I-NT-3 into the eye, ϳ3-4 pg (450 -600 cpm) of 125 I-NT-3 was present in the synaptosomal fraction, but only a fraction of this amount (ϳ1 pg Ϸ100 -200 cpm) was recovered per tectum after washes, resuspension, and warming to 37°C. The radioactivity in the supernatant after Figure 1 . Quantification of radiolabeled NT-3 in retinotectal terminals after anterograde axonal transport. A, Quantification of 125 I-NT-3 in the synaptosomal peak after centrifugation on ficoll-sucrose gradients and fractionation. The synaptosomal peak (SY) and the general membrane fraction (GM) are indicated. B, Synaptosome shows a silver grain (arrowhead) next to a large dense core vesicle (arrow). C, Quantification of silver grains over synaptosomes shows majority of grains over synaptosomes. Silver grains (n ϭ 94) were randomly analyzed. D, Synapse before release of NT-3. Cluster of silver grains over a presynaptic terminal in layer f of the stratum griseum et fibrosum superficiale (SGFSf) of the optic tectum after anterograde transport. Note the synaptic profile ( S). E, Synapse in the process of releasing NT-3. Silver grains over a presynaptic profile ( S) containing a large dense core vesicle (arrow) and over a postsynaptic organelle reminiscent of a multivesicular body (arrowhead). F, Synapse after release of NT-3. Silver grain on the postsynaptic side of the synapse ( S) overlying a multivesicular body (MVB). Scale bars, 200 nm. centrifugation ranged from 30 to 60%, and this amount was not increased when synaptosomes were resuspended in high K ϩ buffer instead of low K ϩ buffer (data not shown). The radioactivity in the supernatant likely represents 125 I-NT-3 that leaked out of damaged immature synaptosomes, thus yielding a relatively high and variable background that made it impossible to measure secreted 125 I-NT-3. The radioactivity levels in this prep were approximately three orders of magnitude lower than what is ϩ shows lack of basal (constitutive) release. Numbers of experiments are indicated on bars. F, Release of radiolabeled tetanus toxin C fragment (Tet tox) was not statistically significant in high K ϩ buffer. G, Radiolabeled cytochrome c (Cyt. C) was not released in high K ϩ buffer compared with low K ϩ buffer. H, Depolarized tecta showed a 25-50% release of substance P (SP) from tectal terminals, measured by radioimmunoassay in 500 l samples (1:6 dilution). *p Յ 0.05, t test, HiK versus LoK, 60 min, error bars indicate SEM. I, When homogenized tecta were incubated with radiolabeled NT-3, NGF, or cytochrome c (Cyt C), NT-3 bound to tectal terminals which was competed by excess cold NT-3, whereas NGF and cytochrome c showed very little binding. SY, Synaptosomal peak; GM, general membrane fraction. usually used for synaptosomal release studies (AndroutsellisTheotokis et al., 1996) , and it was impossible to increase the amount of anterogradely transported 125 I-NT-3 per tectum, because its transport into synapses saturated at ϳ10 ϫ 10 6 cpm/eye ( Fig. 2 B, C) . We conclude that the measurement of anterogradely transported 125 I-NT-3 release directly from synaptosomes is impossible with the conventional technique.
Depolarization of tectal terminals induces release of NT-3
Next we tested whether release of NT-3 from terminals in intact tissue can be measured by quantifying the amount remaining within terminals rather than measuring the amount that is released. Tecta whose retinotectal terminals had been loaded with anterogradely transported 125 I-NT-3 were incubated in oxygenated buffer containing high K ϩ (56 mM), whereas control tecta were incubated in low K ϩ (5 mM), and the amount of 125 I-NT-3 remaining in terminals was quantified by measuring the amount in the synaptosomal fraction relative to the total amount in the tectum or the total amount in the ficoll-sucrose gradient tube. Depolarization resulted in smaller synaptosomal peaks of 125 I-NT-3 (Fig. 2 D) , equivalent to a loss of 15-20% of the radioactivity in the terminals after depolarization ( p Յ 0.001; ANOVA; multiple comparisons). These data were normalized to the total amount of radioactivity in the gradient ultracentrifugation tube. With an input of 40 -80 ng of 125 I-NT-3 in the eye, we found that ϳ8000 -12,000 cpm was transported to the tectum, and 6% (ϳ500 cpm) of this amount was reliably measured in the synaptosomal peak (Table 1) . No basal release of NT-3 was detected during the 60 min incubation step in low K ϩ buffer (Fig. 2 E) . To determine whether the release of 125 I-NT-3 was specific or merely reflected the loss of 10 -15% of presynaptic protein attributable to stimulated release, the total protein content of synaptosomal preparations was compared between depolarized and control tecta. There was no significant difference between the two groups (data not shown), indicating that NT-3 was specifically released. These data show that the novel release assay has significant advantages over the conventional assay in terms of recovery, reliability, and sensitivity, primarily because the synaptosomes are used merely to determine the amount of radiolabeled NT-3. Because the release has occurred in primarily intact tissue (the tectum), the assay does not require the synaptosomes to be functionally intact, which is a major challenge for immature synaptosomes prone to leakage at 37°C.
Control experiments with other transported proteins: limitations of the new assay
To determine whether the release of 125 I-NT-3 was specific or whether other proteins were released similarly when measured with the same assay, we compared the transport, synaptic accumulation, and release of NT-3, NGF, tetanus toxin, and cytochrome c. The novel assay requires that the protein is retained in the eye (to be internalized by retinal ganglion cells), that it be transported to the terminals in the tectum with sufficient efficiency, and that it accumulate in the retinotectal terminals. The data showing how these three requirements are met for five different proteins are summarized in Table 1 . Cytochrome c showed the highest retention in the eye (47%) after 20 hr, and HSP showed the lowest (2%). The transport efficiencies of NT-3, NGF, and cytochrome c were similar (1-2 pg/ng in the tectum retained in the eye) and was significantly more efficient for tetanus toxin (4 pg/ng in the eye). The greatest differences between the proteins were found with synaptic accumulation: NT-3 accumulated in terminals almost six times more than NGF, whereas tetanus toxin and cytochrome c accumulated only slightly more than NGF (Table 1) . These data provide evidence for some remarkable differences in the trafficking of these proteins in the retinotectal system. When we attempted to determine release of NGF in high K ϩ buffer, it turned out that the counts per minutes amounts in the synaptosomal fractions were too low to be reliably quantified (Table 1) . Release of tetanus toxin could be quantified in this system; although there was a trend for lower peaks with depolarization, the difference did not reach statistical significance (Fig. 2 F) . Release of 125 I-cytochrome c could also be quantified, and there was no release of this protein with high K ϩ buffer (Fig.  2G) . NGF transport appeared to be more efficient than in a previous study (von Bartheld et al., 1996) , probably because here we measured radioactivity exclusively in the tectum, and free iodine and degradation products were not removed by dehydration of the tissue. Together, these data show that 125 I-NT-3 is specifically stored in retinotectal terminals, and this capacity makes it possible to quantify release of NT-3, which is released during depolarization, unlike other proteins that can also be transported to retinotectal terminals but do not accumulate there. Requirements and limitations of our novel release assay thus include the following: (1) internalization by projection neurons; (2) anterograde axonal transport; (3) accumulation of the transported protein in presynaptic terminals; and (4) release of the protein from the terminal. The utility of this assay may be useful for any protein and neuronal projection system in which sufficient amounts of protein can be quantified, and the novel assay thus may not be restricted to NT-3 and the retinotectal system of chick embryos.
Control experiments with substance P
A fraction of retinotectal projections in chicken use SP as a neurotransmitter (Yamagata and Sanes, 1995) , and release of SP from synaptosomes can be induced by treatment with high K ϩ (Lembeck et al., 1977) . Radiolabeled SP was very poorly transported anterogradely by RGCs after injection in the eye (Table  1) , presumably attributable to the lack of SP receptors on RGCs that transport endogenous SP, and therefore it was not possible to measure release of (exogenous) SP from retinotectal terminals.
To determine whether depolarization of tecta induces release of endogenous SP from tectal terminals, similar to that of anterogradely transported NT-3, synaptosomal fractions were prepared from 125 I-NT-3-loaded tecta (to identify the synaptosomal peaks), and the amount of SP in the synaptosomal peak after depolarization (or maintenance of tecta in low K ϩ buffer as controls) was measured by radioimmunoassay (Chen et al., 1996) . Approximately 25-50% of SP was released by depolarization ( Fig. 2 H) , which is similar to amounts of other neuropeptides released from synaptosomes (25%) (Verhage et al., 1991b) . These data confirm the validity of our release protocol by comparison with a classical neuropeptide.
Control experiments with added neurotrophins or cytochrome c
Release of neuropeptides exclusively from terminals is conventionally examined by measuring the release from synaptosomes (Androutsellis-Theotokis et al., 1996) rather than examining the release in intact tissue and then preparing synaptosomes to measure the amount remaining. To determine whether neurotrophins and other small peptides bind to synaptosomes prepared from E17 chick tecta, homogenized tecta were incubated for 15-20 min with radiolabeled neurotrophins or radiolabeled cytochrome c, and the tissue was processed as described. Significant amounts of BDNF and NT-3 accumulated in the synaposomal peak, but very little NGF or cytochrome c accumulated (Fig. 2 I) . To test whether binding of BDNF and NT-3 to synaptosomes was receptor mediated, radiolabeled BDNF and NT-3 were incubated in the presence of 500-fold excess cold same trophic factor. Much of the BDNF (data not shown) and NT-3 (Fig. 2 I) bound to synaptosomes in a receptor-mediated manner. These data indicate that NT-3 receptors [presumably tyrosine kinase receptor C (trkC)] are present on tectal terminals (not necessarily retinotectal terminals). These data also show that release of NT-3 from synaptosomes in a static release system likely would fail or grossly underestimate release, because the released NT-3 would bind to receptors present on synaptosomal membranes, thus confounding the results.
Calcium dependence of NT-3 release
To determine whether the depolarization-induced release of NT-3 required physiological concentrations of extracellular calcium, 125 I-NT-3-loaded tecta were incubated in calcium-free buffer containing the calcium chelator BAPTA. High concentrations of BAPTA (200 M) abolished the high K ϩ -induced release of NT-3 (Fig. 3A) , whereas lower concentrations (20 M) did not ( Table 2 ), indicating that the lower concentration of BAPTA was not sufficient to chelate the calcium that may leak from the dissected tecta into the buffer (volume of 3 ml). To determine whether this was indeed the case, calcium was measured in buffers with and without tecta in four conditions (0 M, 20 M, and 200 M BAPTA and 10 M BAPTA AM) in calcium-free buffers and in addition in normal calcium buffers as shown in Table 2 . Calcium leakage from tecta increased the calcium concentration in calcium-free buffers from ϳ3 to ϳ6 M, and this increase was not significantly attenuated by 20 M BAPTA. BAPTA at 200 M reliably reduced the calcium concentration in these buffers to Ͻ1 M calcium. BAPTA AM at 10 M did not reduce the extracellular calcium concentration significantly. We will refer to the 2 mM calcium concentration as "normal calcium," to the 2-10 M calcium concentration as "low calcium," and to buffers with Յ 1 M calcium concentration as "calcium-free" buffers. It should be noted that the effective calcium concentration at the nerve terminals within the tectum likely differs from the calcium concentration that was measured in the incubation buffer.
To examine whether functional voltage-gated calcium channels were required for depolarization-induced NT-3 release, tecta were incubated in normal calcium buffer containing 100 M cadmium chloride, a nonselective blocker of voltage-gated Ca 2ϩ channels. Cadmium significantly reduced the K ϩ -evoked NT-3 release (Fig. 3A) . To determine whether functional N-type calcium channels were required for NT-3 release, tecta were incubated in buffer containing 0.1 M -conotoxin, an N-type Ca 2ϩ channel blocker. -Conotoxin significantly reduced NT-3 release (Fig. 3A) , consistent with the localization of N-type calcium channels on presynaptic terminals (Westenbroek et al., 1992) . Nifedipine (10 M), a blocker of L-type Ca 2ϩ channels, showed no significant effect on release (Fig. 3A ). These data demonstrate that high K ϩ -induced release of NT-3 depends on extracellular calcium, which, during depolarization, enters the synapse via N-type calcium channels.
Release of neurotrophins from brain slices and cultured neurons depends on mobilization of calcium from intracellular stores (Blöchl and Thoenen, 1995; Thoenen, 1995; Griesbeck et al., 1999) . To test whether NT-3 release from axon terminals also required intracellular calcium release, tecta were incubated in low calcium buffer containing the membrane-permeable calcium chelator BAPTA AM at 10 M (calcium concentrations of 4 -6 M) ( Table 2) . BAPTA AM effectively chelates calcium only after membrane penetration, cleavage by intracellular esterases, and intracellular accumulation (Tsien, 1981) . The amount of extracellular calcium (4 -6 M) remaining in the BAPTA AM-treated solution would have been sufficient to allow for the release of NT-3 (compare with 20 M BAPTA in Table 2 ). Addition of the relatively small amount of 10 M BAPTA AM significantly attenuated the release of NT-3 (Fig. 3A) . To verify that mobilization of calcium from intracellular stores affects NT-3 release, three experiments were performed. Dantrolene, an inhibitor of calcium release from caffeine-sensitive intracellular stores (Blöchl and Thoenen, 1995) , was used at 50 M in both low calcium and normal calcium high K ϩ buffer to determine whether it would prevent the release of NT-3. In both low calcium and in normal calcium buffer (as defined in Table 2 ), dantrolene completely prevented the release of NT-3 (data shown for low calcium in Fig.  3A) . These experiments indicate that high K ϩ -induced NT-3 release requires the release of calcium from intracellular stores (calcium-induced calcium release). The role of intracellular calcium was further tested by incubation in 1 mM 4-aminopyridine (4-AP) in normal calcium buffer, which increases intracellular (cytosolic) calcium and has been suggested to cause the release of trophic factors (Grimaldi et al., 2001 ). 4-AP caused significant NT-3 release (Fig. 3A) . Finally, to verify that mobilization of calcium from intracellular stores and subsequent increase in intracellular calcium is sufficient to induce release of NT-3, tecta loaded with 125 I-NT-3 were incubated in high K ϩ buffer containing 5 M thapsigargin. Thapsigargin induced a greater release of NT-3 than depolarization alone (Fig. 3A) . When thapsigargin was tested in low K ϩ buffer, the evoked NT-3 release was of a similar magnitude as seen with thapsigargin in high K ϩ buffer (Fig. 3A) . It should be noted that thapsigargin acutely induces a transient calcium spike by mobilizing calcium from intracellular stores. This acute effect is distinct from the chronic effects of thapsigargin because of the depletion of intracellular calcium stores that can be seen in dynamic (superfusion) release assays. Such longterm effects of thapsigargin would not be seen in our release assay, because NT-3 is not replenished as shown by colchicine experiments (see below). Such considerations have to be kept in mind when interpreting data obtained with our novel release assay. To verify that the mobilization of calcium from intracellular stores by thapsigargin is immediate and does not require 60 min of incubation, we tested whether NT-3 was released within Ͻ10 min incubation. As expected, the effect of thapsigargin on NT-3 release was virtually identical within 10 min (data not shown) and 60 min. Together, these data indicate that mobilization of calcium from intracellular stores is sufficient to trigger release of NT-3 from terminals.
Role of cAMP and CaM kinase II
cAMP has been implicated in the regulation of release of transmitters and neurotrophins (Edwards et al., 1988; Thoenen, 1995; Goodman et al., 1996) . To determine whether cAMP is involved in NT-3 release, we used the cAMP analog 8-Br-cAMP and forskolin. Tecta were incubated in low K ϩ buffer containing 50 M 8-Br-cAMP. This drug induced NT-3 release (Fig. 3B) , consistent with the notion that cAMP is involved in the release mechanism. NT-3 release was also induced by 10 M forskolin, an adenylate cyclase activator (Fig. 3B) . Thus, two distinct ways to elevate cAMP levels showed the same result, namely release of NT-3, further supporting the notion that cAMP indeed is involved in the regulation of NT-3 release. Protein kinases regulate synaptic transmission, with the most direct evidence for Ca 2ϩ / calmodulin-dependent protein kinase II (CaM kinase II) (Llinas Kelly, 1993) . To test whether CaM kinase II affects NT-3 release, we used the selective inhibitor, KN-93, at doses which primarily abolish the activity of CaM kinase II, but not of other kinases (10 M) (Sumi et al., 1991) . As a control, we used the inactive analog, KN-92 (10 M). KN-93 significantly reduced high K ϩ -induced NT-3 release, whereas KN-92 had no effect (Fig. 3B) . These data indicate that cAMP and CaM kinase II may act downstream of the depolarization induced by high K ϩ .
Role of extracellular sodium
The role of extracellular sodium for the release of neurotrophins is controversial. Initial studies on the release of neurotrophins concluded that extracellular sodium is required for regulated release of neurotrophins from dendritic and somal compartments (Blöchl and Thoenen, 1995) , but this may have been attributable to an independent blocking effect of the sodium substitute, N-methyl-D-glucamine (NMG) (Hoener, 2000) . Release of neuropeptides from terminals (rather than whole cells) does seem to require sodium influx (Stuenkel and Nordmann, 1993; Thirion et al., 1999) . To determine whether low extracellular sodium may attenuate NT-3 release from axon terminals, 125 I-NT-3 loaded tecta were incubated in buffer containing high K ϩ , and NMG to replace Ͼ 90% of the extracellular sodium. As seen in Figure 3B , replacement of sodium reduced the release of NT-3. When NMG was washed out and the buffer replaced with normal sodium, high K ϩ buffer induced NT-3 release (data not shown), indicating that the effect of NMG was reversible. To determine whether the opposite treatment, increased influx of sodium rather than decreased influx as with NMG, will have the opposite effect on NT-3 release, we used strophanthidin, a sodium-potassium ATPase inhibitor (Meyer and Cooper, 1981) . As expected, incubation of tecta with 500 M strophanthidin induced release of NT-3 (Fig.  3B) . Release was not attenuated by incubation with tetrodotoxin (TTX, 3 M) (Fig. 3B) , indicating that TTX-sensitive sodium channels are not required for the release process when induced by high K ϩ . Together, these results may suggest that an unconventional sodium-dependence of neurotrophin release may be a general feature for neuropeptide release from axon terminals (Stuenkel and Nordmann, 1993; Thirion et al., 1999) .
Structural proteins involved in NT-3 release
Microtubules and microfilaments have been implicated in the movement of vesicles from the axon shaft to the membrane at nerve terminals for exocytosis (Westrum et al., 1983; Hirokawa et al., 1989; Ashton and Dolly, 1991) . Microfilaments are thought to act as a barrier to small synaptic vesicle (SSV) fusion, but they may aid in the translocation of LDCVs (Doussau and Augustine, 2000) and LDCVs are known to concentrate outside the active zone (Verhage et al., 1991a) . To determine whether microfilaments are required for NT-3 release, tecta were incubated with 0.2 M cytochalasin D. This drug significantly reduced NT-3 release (Fig. 4 A) . Microtubules are present in tectal nerve terminals (Bird, 1989) . To determine whether intact microtubules are required for evoked NT-3 release, 125 I-NT-3 loaded tecta were incubated in high K ϩ buffer containing 175 M colchicine. Colchicine abolished the release of NT-3 (Fig. 4 A) , indicating that intact microtubules are necessary for evoked NT-3 release from axon terminals. The colchicine experiments also show that there is no significant replenishment of NT-3 from axons into terminals during the 60 min release period. If the released NT-3 was rapidly replenished by anterograde flow from the axon, one would not expect a net loss of NT-3 in terminals. Because colchicine blocks all anterograde axonal transport of NT-3 (von Bartheld et al., 1996) , we can exclude this possibility.
Role of synaptobrevin/synaptobrevin analogs in NT-3 release
Synaptobrevin and synaptobrevin analogs are required for release of neurotrophins from cell bodies and/or dendrites (Blöchl, 1998) . Synaptobrevin can be cleaved by tetanus toxin (Schiavo et al., 2000) . To determine whether tetanus toxin treatment affects NT-3 release from terminals, tecta were pretreated by intraocular injection of the whole tetanus toxin (1-2 g) which is subsequently transported anterogradely to the retinotectal terminals (Manning et al., 1990) . To verify this mode of drug delivery, 300 ng of radiolabeled tetanus toxin C-fragment was injected into the eye of chick embryos. Within 24 -48 hr, 1 ng of the toxin accumulated in the retinotectal axons and terminals (Fig. 4 B) . Subsequent anterograde transport of 125 I-NT-3 to the tectum was not affected by intraocular injection of 1-2 g tetanus toxin (Fig. 4C) . Tetanus toxin in the retinotectal terminals (estimated 5 ng/tectum) reduced the release of NT-3 from tectal terminals (Fig. 4 A) . This suggests that intact synaptobrevin (or synaptobrevin analogs) are required for the release of NT-3 from axon terminals, and that at least some of the release is accomplished by synaptobrevin-mediated vesicle trafficking and/or exocytosis.
Requirements for the effect of thapsigargin on NT-3 release
Are extracellular sodium, calcium, or intact microtubules required for the effect of thapsigargin? When tecta were cotreated with NMG and thapsigargin, there was no significant reduction in the amount of NT-3 that was released (Fig. 4 D) , indicating that the effect of thapsigargin did not require extracellular sodium. Thapsigargin did not require the influx of extracellular calcium for triggering release, because incubation in calcium-free solution containing 200 M BAPTA did not reduce the magnitude of release (Fig. 4 D) . When colchicine treatment was combined with thapsigargin, there was a significant reduction in the amount of NT-3 that was released (Fig. 4 D) , indicating that colchicine may act downstream of the mobilization of calcium from internal stores. These data indicate that mobilization of calcium from intracellular stores is sufficient to trigger NT-3 release, but requires intact microtubules, presumably for vesicle translocation (Doussau and Augustine, 2000) .
Kainic acid induces NT-3 release in vivo
Kainic acid and tetrodotoxin increase and decrease, respectively, the electrical activity of RGCs (Catsicas and Clarke, 1987; Karlsson and Hallböök, 1998) . To determine whether stimulation of RGCs in vivo induces release of NT-3 similar to the depolarization of retinotectal terminals in vitro, 1 g kainic acid or PBS vehicle control was injected in the eyes of chick embryos in ovo, 19 hr after intraocular injection of 125 I-NT-3. The final concentration of kainic acid in the eye (Ϸ 80 l volume) was estimated to be 62 M. Animals were killed 45 min after the intraocular injection of kainic acid, and their tecta were processed immediately for synaptosomal fractionation. Kainic acid induced the release of ϳ30% of the exogenous NT-3 present in the terminals (Fig. 5) . To determine whether this effect of kainic acid could be blocked by treatment with tetrodotoxin (TTX), the eyes of embryos were pretreated with TTX (0.16 g injected, final concen- tration estimated at 6.25 M), 20 min before the injection of kainic acid. TTX treatment abolished the effect of kainic acid (Fig. 5B ). These data confirm in an in vivo experiment the results from our exposure to drugs by bath application of whole tecta.
Is NT-3 packaged in large dense core vesicles?
Our ultrastructural autoradiography localized 125 I-NT-3 in the vicinity of large dense core vesicles (LDCVs) (Fig. 1 E) , but the resolution of the 125 I-autoradiography was not sufficient for unambiguous identification of the types of vesicles which contain NT-3 in presynaptic terminals. Therefore, vesicles of different sizes were purified by differential sedimentation in sucrose gradients (Huttner et al., 1983; Han and Fischbach, 1999) . Vesicle purification showed that only the anterogradely transported 125 I-NT-3 accumulated in fractions known to contain LDCVs (Han and Fischbach, 1999) , but not the 125 I-NT-3 that was incubated with synaptosomes ( Fig. 6 A) . After incubation, 125 I-NT-3 was marginally increased in fractions containing SSVs. Because the LDCVs are heterogeneous in size and the fractions containing LDCVs also contain endosomes, these data do not prove that the anterogradely transported NT-3 is exclusively associated with LDCVs, but our data are consistent with this notion. When the superficial layer of the optic tectum of E17 chick embryos was immunolabeled for endogenous NT-3 and examined at the electron microscopic level, immunolabel was detected in LDCVs (Fig. 6 B) . We estimate that ϳ25% of terminals in retinorecipient layers of the tectum contained LDCVs, and ϳ5-6% of such terminals contained LDCVs with NT-3-like immunoreactivity. No labeled LDCVs were detected when the primary antibody was omitted (data not shown). If 125 I-NT-3 was present in LDCVs within retinal axons, one would expect to see silver grains over LDCVs in the stratum opticum (SO) within the tectum. Indeed, we found silver grains over and adjacent to dense-cored vesicles within axons of the SO (Fig. 6C) . Because of the relatively small size of the LDCVs and the fact that many silver grains may obscure them, we did not attempt to quantify the correlation of silver grains and LDCVs. Taken together, these results further support the idea that anterogradely transported neurotrophins are packaged in LDCVs. I-NT-3 shows higher levels of radioactivity in sedimentation fractions known to contain LDCVs in chick embryo brains (Han and Fischbach, 1999) , but not in fractions known to contain SSVs (top panel). When homogenized tecta were incubated with 125 I-NT-3 (bottom panel), radioactivity was seen in sedimentation fractions known to accumulate SSVs (Han and Fischbach, 1999) . B, Section through a retinotectal terminal from a 17-d-old chick embryo immunolabeled with an antibody to NT-3, processed with horseradish-peroxidase, and visualized with diaminobenzidine. Note reaction product in a large dense core vesicle (arrow). Scale bar, 100 nm. C, Section through the stratum opticum (SO) of the optic tectum after injection of 125 I-NT-3 in the eye. Note a cluster of silver grains in the vicinity of a large dense core vesicle (arrow) in sectioned retinotectal fibers. Scale bar, 500 nm.
DISCUSSION
Our study provides first direct evidence for mechanisms of release of anterogradely transported neurotrophins from axon terminals. We found that NT-3 is released by depolarization, that this release depends on intracellular and extracellular calcium, and can be evoked by mobilization of calcium from intracellular stores. Release is further regulated by cAMP and CaM kinase II. We show that release occurs by exocytosis of presumptive large dense-core vesicles (LDCVs). Anterogradely transported and presynaptically located neurotrophins are released by changes in local, intracellular calcium concentrations.
Technical considerations
Previous studies used immunological techniques to measure the amounts of neurotrophins released from entire cells (cell bodies, dendrites and axons) into medium or perfusate (Blöchl and Thoenen, 1995; Goodman et al., 1996) , but this technology was not sufficiently sensitive to measure the excessively small amounts (molecules per synapse) exclusively released from axon terminals. Therefore, it is important to consider whether we accurately measured the amount of 125 I-NT-3 in retinotectal terminals by synaptosomal fractionation and gamma counting. When synaptosomal measurements were compared with quantitative analysis of the in situ distribution of silver grains after autoradiography at the ultrastructural level, the morphological and the biochemical/pharmacological data showed a remarkable agreement for the estimates of exogenous NT-3 in axon terminals (5.48% vs. 5.94%).
Another important issue is whether anterogradely transported exogenous NT-3 is released by the same mechanisms as anterogradely transported endogenous NT-3. Do endogenous and exogenous neurotrophins pass through the same organelles? RGCs in chicks express NT-3, and endogenous NT-3 is anterogradely transported to the terminals in the optic tectum (von . Proteins destined for anterograde transport have to be processed in the Golgi system (Hammerschlag et al., 1982) . Exogenous NT-3 (but very little BDNF) accumulates in the Golgi system of RGCs von Bartheld et al., 2001) and transcytoses RGCs in a receptor-mediated manner, possibly by sequential binding to trkC and p75 receptors . Therefore, it is likely that exogenous NT-3 joins the pathway normally taken by endogenous NT-3. Alternatively, there may be parallel pathways of release, one for newly synthesized NT-3, and one for transcytosed NT-3 (von Bartheld et al., 2001) .
Our release assay has significant advantages (sensitivity and synapse specificity) as well as limitations compared with conventional release assays. It requires sufficient internalization, anterograde axonal transport, and accumulation of the protein in presynaptic terminals, and it is not a dynamic assay with replenishment of the source. Nevertheless, its utility is not necessarily restricted to the retinotectal system or to neurotrophins.
Molecular determinants of NT-3 release
Our results discern 3 major steps that lead to the release of NT-3 from axon terminals (Fig. 7) . These conclusions are based on data obtained with a variety of pharmacological agents at concentrations commonly used for tissue slices. The first step involves depolarization of the axon terminus with influx of calcium through N-type calcium channels. The second step may be induced by calcium influx and/or mobilization of calcium from intracellular stores. Increased calcium concentrations in the presynaptic compartment (Verhage et al., 1991a) , as well as kinase activation (cyclic AMP-dependent kinases and CaM kinase II), may provide signals for vesicle translocation via microtubules to the active zone at the synaptic cleft. The vesicle then fuses with the membrane, presumably mediated by synaptobrevin, because release is tetanus-toxin-sensitive. The neurotrophin is released and may diffuse in the synaptic cleft to bind to presynaptic and/or postsynaptic neurotrophin receptors (Levine et al., 1995; Wu et al., 1996; Kafitz et al., 1999; von Bartheld et al., 2001) . The role of sodium influx for neurotrophin release from whole cells is controversial (Blöchl and Thoenen, 1995; Hoener, 2000) . We find that NT-3 release from terminals requires sodium influx, apparently via TTX-insensitive sodium channels, consistent with reports of TTX-insensitive, sodium-evoked release of neuropeptides from axon terminals (Stuenkel and Nordmann, 1993) and sodium influx into docked vesicles (Thirion et al., 1999) . Sodium influx may also interact with mobilization of calcium from internal stores (Berridge, 1998) .
Release from different compartments is regulated by different mechanisms
Potassium-stimulated release of neuropeptides is typically mediated by activation of L-type calcium channels (Trimble et al., 1991; Meir et al., 1999) , but release from terminals is often mediated via N-type channels, consistent with their localization in terminals (Westenbroek et al., 1992; Simmons et al., 1995) . Our study is the first to examine mechanisms of the release of anterogradely transported neurotrophins. Previous studies on the release of neurotrophins could not discriminate between different compartments (dendrites, soma, and axons) (Blöchl and Thoenen, 1995; Goodman et al., 1996; Blöchl, 1998 ; Griesbeck et Figure 7 . Diagram summarizes the proposed mechanisms of release of anterogradely transported NT-3 from axon terminals. Depolarization by high potassium (K ϩ ) opens N-type calcium channels. Calcium influx induces calcium release from internal stores. Increased intraterminal calcium concentrations are sufficient to induce release of NT-3 containing vesicles. Release can also be induced by cAMP and requires CaM kinase II activity. Second messengers and kinases may act directly on vesicle release or indirectly via calcium mobilization from internal stores (Hille et al., 1999) . Translocation of the NT-3-containing vesicle requires intact microtubules and microfilaments, and fusion of the vesicle depends on synaptobrevin or synaptobrevin-like molecules. Once released, NT-3 diffuses across the synaptic cleft, binds to trkC receptors, is internalized, and accumulates postsynaptically in multivesicular bodies (MVB).
